Cargando…
Rheocarna(®) as an alternative therapeutic option for patients with chronic limb-threatening ischemia: A case report
Recently, a new low-density lipoprotein apheresis device (Rheocarna(®); Kaneka Corporation, Osaka, Japan), a blood purification therapy, was approved in Japan for managing chronic limb-threatening ischemia with refractory ulcers. Here, we describe a case of chronic limb-threatening ischemia that was...
Autores principales: | Satake, Akinori, Nakano, Yusuke, Niwa, Toru, Ando, Hirohiko, Takashima, Hiroaki, Amano, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850122/ https://www.ncbi.nlm.nih.gov/pubmed/36686205 http://dx.doi.org/10.1177/2050313X221149359 |
Ejemplares similares
-
Rheocarna(®) therapy after distal bypass surgery
por: Nakamura, Yasuhito, et al.
Publicado: (2023) -
Dynamic Changes in Coronary Flow Pattern During Transcatheter Aortic Valve Replacement in Severe Aortic Stenosis
por: Suzuki, Wataru, et al.
Publicado: (2021) -
Stakeholder Values and Preferences in Lower Limb Amputation for No-Option Chronic Limb Threatening Ischemia
por: Nieuwstraten, Jelle A, et al.
Publicado: (2021) -
Impact of ivabradine in decompensated heart failure due to cancer therapy‐related cardiac dysfunction
por: Nakano, Yusuke, et al.
Publicado: (2021) -
Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients
por: Onishi, Tomohiro, et al.
Publicado: (2021)